In this issue of Neuron, Sittig et al. (2016) present research that calls into question the way laboratory mice are used to address questions in basic science and experimental medicine. This research demonstrates strong interactions between mutant alleles and genetic background.
In 1981 the US National Academy of Sciences published a report from a committee of experts who had been asked to comment on selection of mammals suitable for aging research (Committee on Animal Models for Aging Research, 1981) . In their chapter on inbred mice, they noted that such stocks had ''been developed for particular research purposes (e.g. the study of particular disease entities) and, therefore, may not be suitable for research on aging.'' They noted that mice captured from wild sources and then adapted to laboratory husbandry conditions would inevitably undergo strong genetic selection which would ''inadvertently restrict the gene pool.'' And indeed laboratory mice differ from actual mice, the kind found in barns, in multiple dimensions relevant to aging, neuroscience, and most other forms of biomedical research. Laboratory mice are far larger, mature much more quickly, have litters about twice the size as those produced by wild mice in laboratory conditions (Miller et al., 2002) , are often deaf within their first year of life (Johnson et al., 2000) , can no longer make pineal hormones needed for sensing circadian and seasonal cues (Ebihara et al., 1986) , and tend to prefer getting into cages than fleeing from them. Forced homozygosity of harmful recessive alleles terminates most incipient strains during the inbreeding process, and the few gene combinations that can survive the inbreeding process are typically afflicted by disabilities and physiological peculiarities not seen in more diverse stocks or in actual wild mice. Crosses between two inbred mouse stocks, to generate an F1 hybrid, are nearly always longer lived than either parent (Smith et al., 1973) .
Because inbred genotypes are not that good at making a mouse, phenotypic variability for most traits in inbred mice, as in inbred flies, is almost always higher (sic) than in F1 hybrids (Phelan and Austad, 1994) .
The National Academy of Sciences report (Committee on Animal Models for Aging Research, 1981) recommended some good alternatives, specifically the use of F2 hybrids, four-way crosses, and diallel crosses, each of which can ''provide replicable populations of genetically heterogeneous subjects.populations in which genetic segregation is occurring, but in which the gene pool can be reproduced'' by crossing the progenitor genotypes. Use of a single genotype (a set of identical quintuplets, for example) for a human clinical study would be a ludicrous error, since the value of a research study depends largely on the extent to which the findings are robust, i.e., can be generalized beyond the specific members of the tested population. A clinical study restricted to people with a specific, rare, combination of autosomal recessive diseases would also be viewed as suspect. And yet nearly all biomedical research with mice uses inbred stocks, very often C57BL/6 (B6), and the tenuous assumption that the findings will pertain to ''mice in general,'' or even to a second arbitrarily chosen stock, is as invisible as water is to a fish (Wallace, 2005) . A few brave pioneers, fighting upstream against the torrent, have begun to use genetically segregating stocks routinely, including for example the use of four-way cross mice for exploratory studies of drug effects on mouse lifespan (Miller et al., 2007) . Similarly, the production of carefully maintained outbred stocks, and of appropriately large sets of diallel crosses (Chesler, 2014) , is just now starting to gain traction beyond the circle of its specialist originators. Nonetheless, in 2014, 94% of requests for mice from the NIA's aging mouse colony requested B6 animals, 3% requested another inbred stock, and only 3% requested F1 hybrid mice (N. Nadon, personal communication). An effort by NIA to distribute aged mice of a genetically heterogeneous four-way cross stock was ended after six years because of lack of demand from the research community.
This issue of Neuron contains a compelling demonstration of the risks of such tunnel vision (Sittig et al., 2016) . Sittig, Palmer, and their colleagues studied two mutations, one (Cacna1c) associated with psychiatric diseases in people and behavioral abnormalities in mice, and the other (Tcf7l2) with effects on metabolic and behavioral endpoints in both mice and humans. B6 males carrying one of these two mutant alleles were bred to female mice from each of 30 inbred strains, thus generating a set of 30 different F1 hybrid stocks for each mutant. Within each F1 stock, half the mice carried the mutation of interest. Mutant and nonmutant mice were then tested for relevant behavioral and metabolic endpoints. The key statistic was the interaction effectdid the effect of the mutant allele vary significantly depending on the F1 stock in which it found itself? For the Cacn1c mutation, there were significant [strain 3 mutant] interactions for 4 of the 6 traits, and the same proportion of behavioral tests (4 of 6) showed strain-specific interaction effects for the Tcf67l2 mutation. As the authors note, for some of the traits the effect is quantitative, with mutant effect seen in about half of the tested strains, but not in the other half. For these traits, the conclusion reached in a traditional onestrain study would have depended largely on which specific hybrid stock had been selected at the start of the research work. For other traits, the results are even more dramatic, in that the null mutation produces an effect in one direction in a subset of the stocks, and in the other direction in other F1 hybrids.
The work presented by the Palmer group makes it all the harder to justify using inbred mouse stocks for studies that are intended to reach broad, robust conclusions, for example about effects of mutations, drugs, or diets on mice generally. Inbred mice are highly suitable for an important subset of studies in biomedicine. Many strains of inbred mice develop rare, interesting diseases, early or later in life, whose elucidation can address fundamental questions in pathobiology or shed light on the effects of human mutations with similar clinical presentations. Inbred, or preferably F1 hybrid, mice can be used for protocols in which tissues must be transplanted from a donor to a recipient mouse, in which rejection of the tissue would occur using histo-incompatible mice. Inbred mice are also irreplaceable as the starting ingredients for construction of genetically segregating stocks. These segregating stocks, however, are in general more suitable than inbred mice for most work in biomedical science.
All of the mice used in the Palmer paper (Sittig et al., 2016) are from inbred stocks highly adapted to laboratory husbandry conditions, a perfectly reasonable design decision. An important side issue, one that would have been difficult for Palmer's group to address, is the extent to which behavioral traits modified by the mutant alleles might have been different if evaluated on background genomes that more closely resembled those of wild mice, i.e., mice living under natural conditions and not subjected to 100 or more prior generations of selection for docility and sexual promiscuity, in the absence of predator pressure and thermal stress, and without periods of food scarcity. A hint of the importance of this form of background genetic effect comes from a recent report (Chalfin et al., 2014) showing that behavioral effects of mutant alleles, which were not detectable in a standard laboratory mouse background stock, were revealed after they were crossed into a stock of wild mice not adapted to laboratory husbandry conditions. Using laboratory mouse stocks, or even a panel of F1 hybrid mice (as in Sittig et al., 2016) , or even using laboratory-derived segregating stocks to evaluate pathobiology of mice, is equivalent to trying to learn more about wolf behavior through the study of poodles or corgis.
A question like ''does this gene modify glucose levels (or health or cognition or cardiac function) in mice'' is fundamentally of greater interest than the question ''does this gene modify glucose levels in C57BL/6J mice?'' Why, then, do researchers persist in using inbred mice (and rats) for studies intended to reach robust general conclusions? Partly, this may reflect a fixed, intuitive belief that homozygosity will diminish phenotypic variability and bestow higher statistical power, despite hundreds of papers to the contrary (Phelan and Austad, 1994) . But the key problem seems to be inertia: when one's mentor, and her mentor before her, and her mentor's mentor, used B6 mice, and the reviewers use B6 mice, and the literature is filled with data on B6 mice, and you've always used B6 mice, then use of B6 mice and pretending that they are sort of ''normal,'' in an illdefined and un-tested way, begins to seem like the right way to do science, just as each lemming is pretty sure that the lemming right ahead must know how to get to the beach. Sittig et al. (2016) provide a convincing and detailed refutation to this complacency. It deserves to be widely read, cited by those who wish to obtain permission to use more trustworthy and reliable mouse models in their own research, and emulated by researchers working on other domains of neuroscience and, more generally, by investigators who use mice to address questions in basic bioscience and experimental medicine.
